CYP1A1 and metabolic dysfunction-associated steatotic liver disease: α-naphthoflavone treatment reduced oxidative stress and insulin resistance as well as mitigated NAFLD by modulation of AhR regulated Cyp1a1 and TNFα pathways [90].